dapoxetine on demand

PreclinicalSmall molecule

dapoxetine on demand is one of 28 small molecule programs targeting Premature Ejaculation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature EjaculationActive, not recruiting

Premature EjaculationPreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Premature Ejaculation

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Viagra

VViatris Specialty LLC

Approved

1 3

Cialis

Eli Lilly

Phase 3

2 4

Ultram

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

2 6

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 3

2 7

Botox

AbbVie

Phase 3

1 8

Rapaflo

AbbVie

Phase 2

1 9

Anafranil

SSpecgx

Phase 3

2 10

Standard Treatment

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Premature Ejaculation1 trial

The Impact and Benefit of Physical Activity on Premature Ejaculation

Completed·—·N/A·NCT02844998·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dapoxetine on demand. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dapoxetine on demand compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dapoxetine on demand. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ankara Training and Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAnkara Training and Research Hospital

dapoxetine on demand

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Premature Ejaculation1 trial

References

Drug Info

Quick Facts

Related News